Tag : Iptacopan

CONFERENCE UPDATE

Iptacopan delivers sustained QoL gains and symptom control in PNH: 48-week findings from the APPLY-PNH and APPOINT-PNH trials
Persistent hemolysis and anemia in paroxysmal nocturnal hemoglobinuria (PNH) can significantly impair health-related quality of life (HRQoL) and lead to debilitating symptoms, with fatigue recognized as the most disabling. Despite advancements, a need remains to address these challenges effectively.